Compare BEEM & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | ENLV |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 26.6M |
| IPO Year | N/A | 1995 |
| Metric | BEEM | ENLV |
|---|---|---|
| Price | $1.69 | $0.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | 208.3K | ★ 681.1K |
| Earning Date | 11-14-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,668,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $45.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $0.66 |
| 52 Week High | $4.04 | $2.10 |
| Indicator | BEEM | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 46.43 |
| Support Level | $1.62 | $0.66 |
| Resistance Level | $1.72 | $0.88 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 70.49 | 74.75 |
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.